ECSP034604A - Inhibicion de la dependendia de celulas tumorales del factor de crecimiento - Google Patents

Inhibicion de la dependendia de celulas tumorales del factor de crecimiento

Info

Publication number
ECSP034604A
ECSP034604A EC2003004604A ECSP034604A ECSP034604A EC SP034604 A ECSP034604 A EC SP034604A EC 2003004604 A EC2003004604 A EC 2003004604A EC SP034604 A ECSP034604 A EC SP034604A EC SP034604 A ECSP034604 A EC SP034604A
Authority
EC
Ecuador
Prior art keywords
growth factor
tumor cells
dependendy
inhibition
dependence
Prior art date
Application number
EC2003004604A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Rosemarie Lichtner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP034604A publication Critical patent/ECSP034604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere al uso de inhibidores del receptor de progesterona para inhibir la dependencia de las células tumorales, del factor de crecimiento.
EC2003004604A 2000-10-18 2003-05-14 Inhibicion de la dependendia de celulas tumorales del factor de crecimiento ECSP034604A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen

Publications (1)

Publication Number Publication Date
ECSP034604A true ECSP034604A (es) 2003-06-25

Family

ID=7660193

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004604A ECSP034604A (es) 2000-10-18 2003-05-14 Inhibicion de la dependendia de celulas tumorales del factor de crecimiento

Country Status (10)

Country Link
US (1) US20040157811A1 (es)
AR (1) AR034562A1 (es)
DE (1) DE10051609A1 (es)
EC (1) ECSP034604A (es)
PE (1) PE20020472A1 (es)
PT (1) PT1414465E (es)
TW (1) TWI234458B (es)
UY (1) UY26975A1 (es)
YU (1) YU30003A (es)
ZA (1) ZA200303785B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US20080261933A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
PE20020472A1 (es) 2002-06-15
US20040157811A1 (en) 2004-08-12
UY26975A1 (es) 2002-06-20
DE10051609A1 (de) 2002-05-02
PT1414465E (pt) 2007-01-31
AR034562A1 (es) 2004-03-03
TWI234458B (en) 2005-06-21
YU30003A (sh) 2006-08-17
ZA200303785B (en) 2005-08-29

Similar Documents

Publication Publication Date Title
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
UY27748A1 (es) Derivados de quinolina e isoquinolina, un método para su obtención y su uso como inhibidores de la inflamación.
EA200300105A1 (ru) Нестероидные ингибиторы воспалений
ES2192301T3 (es) Derivados de resorcinol.
BRPI0511111A (pt) compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários
ECSP066539A (es) Derivados 1-amino-2-oxi sustituidos del tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorio
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
MXPA02012042A (es) Compuestos efectivos como agonistas de beta-2-adrenorreceptor, y como inhibidores de pde4.
BR0007864A (pt) Composto, e, uso de um composto
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
BR0116152B1 (pt) aditivo adequado para uso como emulsificador e solubilizador, uso de um aditivo, e, composição.
EE200300156A (et) Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
PA8644701A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
PE20020511A1 (es) Uso de antiprogestinas para la induccion de apoptosis en una celula
PA8668901A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como antiinflamatorios
PT1194158E (pt) Uso da proteina uk 114 para inibir a rejeicao do transplante de orgaos
CR8286A (es) Derivados de piperazina inhibidores de quimioquinas y su uso para tratar miocarditis
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento